Phase 1, Double Blind, Randomized, Parallel-group, Single-dose, Comparative Pharmacokinetic, Safety, Tolerability Study of Exemptia (Adalimumab) injection, solution for subcutaneous use (40 mg/0.8 ml.) with Humira® (Adalimumab) injection, solution for subcutaneous use(40mg/0.8ml) administered to healthy subjects.

Trial Profile

Phase 1, Double Blind, Randomized, Parallel-group, Single-dose, Comparative Pharmacokinetic, Safety, Tolerability Study of Exemptia (Adalimumab) injection, solution for subcutaneous use (40 mg/0.8 ml.) with Humira® (Adalimumab) injection, solution for subcutaneous use(40mg/0.8ml) administered to healthy subjects.

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Mar 2017

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Ankylosing spondylitis; Juvenile rheumatoid arthritis; Psoriatic arthritis; Rheumatoid arthritis
  • Focus Pharmacokinetics
  • Sponsors Rus Biopharm
  • Most Recent Events

    • 06 Mar 2017 Status changed from recruiting to completed.
    • 31 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top